Biotechnology firm Pharming announced on Friday that its net loss in 2008 rose to €26m compared to €21m in the preceding year. Turnover remained stable at €700,000.
The company is planning to register its allergy drug Rhucin, one of its most promising products, for the European and US market this year.
In its statement, Pharming said it was unable to give a concrete forecast for 2009 given the uncertainties in the current economic climate.
‘The Pharming team is confident about the outlook for 2009. Together, we will execute and deliver on our key objectives; the strengthening of the product pipeline and our financial position, said CEO Sijmen de Vries.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation